Belgium
3

EU regulatory: Pharma, medical devices and biotech

logo

Stibbe

More information
Ignace Vernimme and Philippe Campolini lead the life sciences practice at Stibbe, advising on complex compliance and regulatory issues. Vernimme’s experience covers IP, life science, and health products, while Campolini is well versed in advising Belgian and international clients in the medical devices and life sciences industry. The team is adept at handling related litigation, including disputes with Belgian pricing authorities. Louis Bidaine is also noted.
Legal 500 Editorial commentary
Profile
stibbe.com

Testimonials

Collated independently by Legal 500 research team.

  • 'The high level of clients provide a network. The internal legal high level expertise.’

  • 'The individuals I have worked with at Stibbe consistently demonstrate professionalism, exceptional expertise, and a client-focused approach. Partners are highly engaged and readily available, offering invaluable strategic insights. Associates are diligent, detail-oriented, and proactive, often going above and beyond to ensure that all aspects of a matter are handled thoroughly.'

  • 'High level of clients providing a network. The internal legal high-level expertise.'

  • 'Stibbe's EU regulatory team specializing in pharma, medical devices, and biotech stands out for its deep understanding of complex regulatory frameworks and its ability to provide pragmatic, business-oriented solutions. The team is particularly adept at navigating intricate EU legislation, offering clients tailored advice that anticipates both legal and commercial challenges.'

Work highlights

Represented Mylan in proceedings before the Court of Justice of the EU against the European Commission regarding an exemption granted to one of its competitors on the market exclusivity of its product.
Advised CSL Behring Blood on a government tender for the processing of Belgian blood in medicines whereby one pharmaceutical company is granted the exclusivity of this market.
Advised CSL Behring on a new pricing model for advanced therapy medicinal products (ATMPs) whereby the payments for the products are spread out over several years to lighten the financial burden of the social security systems.

Lawyers

Practice head

Ignace Vernimme; Philippe Campolini

Other key lawyers

Louis Bidaine